Lillie Mosaddegh, MD
Ophthalmology · San Francisco, CANPI 1487712071
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 43.2% of the total. Reporting peaked in 2019 at $9,765 and has fallen 85.0% since, to $1,468 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $101.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$10K
- AbbVie$5K
- Alcon$3K
- Eyevance Pharmaceuticals LLC$1K
- Biotissue Holdings Inc.$763
- Glaukos Corporation$595
- plus $2K from 17 others
Across 5 payments — averaging $28,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$144K
What the payments were for
- Consulting fees$10,31045%
- Speaking & faculty fees$390%
- Food & beverage$6,81230%
- Education$5,01822%
- Gifts$190%
- Other$5012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 22 | $9,815 |
| AbbVie(2 entities) | 22 | $5,401 |
| Alcon | 85 | $2,522 |
| Eyevance Pharmaceuticals LLC | 4 | $1,337 |
| Biotissue Holdings Inc. | 29 | $763 |
| Glaukos Corporation | 4 | $595 |
| Sight Sciences, Inc. | 25 | $584 |
| Carl Zeiss Meditec USA, Inc. | 1 | $501 |
| Harrow Eye, LLC | 2 | $356 |
| Oyster Point Pharma, Inc. | 3 | $288 |
| Rxsight Inc | 7 | $106 |
| Bausch & Lomb Americas Inc. | 5 | $104 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $64 |
| Coopervision Inc. | 1 | $44 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Optos, Inc. | 1 | $30 |
| Galderma Laboratories, L.p. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Ivantis, Inc | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$2,260
- Flarex$1,250
- LUMERA$501
- AcrySof IQ PanOptix UV IOL$401
- TYRVAYA$255
- TRIESENCE$209
- iDoseTR$204
- VEVYE$147
- MEIBOMIAN GLAND EVALUATOR$125
- AMO PHACO NEEDLE$111
- Clareon$109
How this compares
$22,700 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 90 | $56,968 |
| Brimonidine Tartrate | 292 | $52,987 |
| Alphagan PBrimonidine Tartrate | 84 | $46,476 |
| XiidraLifitegrast | 25 | $26,686 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $23,623 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $19,529 |
| RhopressaNetarsudil Mesylate | 36 | $14,762 |
| Loteprednol Etabonate | 59 | $13,838 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 42 | $13,624 |
| RestasisCyclosporine | 21 | $12,964 |
| AzoptBrinzolamide | 28 | $12,384 |
| TobradexTobramycin/Dexamethasone | 36 | $9,344 |
| Prednisolone Acetate | 201 | $9,340 |
| Brinzolamide | 34 | $8,727 |
| ZyletTobramycin/Lotepred Etab | 14 | $7,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis, Restasis Multidose | $5,401 | $147,428249 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $21 | $34,29168 claims |
| Bausch & Lomb Americas Inc.Xiidra | $104 | $26,68625 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Zylet | $64 | $21,57573 claims |
| AlconAzopt, Simbrinza | $2,522 | $16,66443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Francisco
- Daniel SchwartzSan Francisco$8M
- Gaurav ShahSan Francisco$620K
- Shan LinSan Francisco$374K
- H TanakaSan Francisco$238K
- Jay StewartSan Francisco$219K
- Scott SoSan Francisco$173K
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.